Have a feature idea you'd love to see implemented?
Let us know!
RLMD Relmada Therapeutics Inc
Price (delayed)
$0.359
Market cap
$10.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.86
Enterprise value
$9.35M
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed
Highlights
The EPS has grown by 23% YoY
Relmada Therapeutics's net income has increased by 22% YoY
RLMD's equity has plunged by 53% YoY and by 23% from the previous quarter
The quick ratio has contracted by 47% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of RLMD
Market
Valuations
Earnings
Shares outstanding
30.17M
Market cap
$10.83M
Enterprise value
$9.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.23
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$86.49M
EBIT
-$86.49M
EBITDA
-$86.49M
Free cash flow
-$53.21M
Per share
Balance sheet
Liquidity
EPS
-$2.86
EPS diluted
-$2.86
Free cash flow per share
-$1.76
Book value per share
$1.58
Revenue per share
$0
TBVPS
$1.85
Total assets
$55.72M
Total liabilities
$8.1M
Debt
$0
Equity
$47.63M
Working capital
$47.62M
Debt to equity
0
Current ratio
6.89
Quick ratio
6.69
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-112.1%
Return on equity
-129.8%
Return on invested capital
-134.3%
Return on capital employed
-181.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLMD stock price
How has the Relmada Therapeutics stock price performed over time
Intraday
-0.66%
1 week
1.79%
1 month
-86.8%
1 year
-89.05%
YTD
-91.33%
QTD
-88.92%
Financial performance
How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$91.64M
Net income
-$86.49M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's net income has increased by 22% YoY
Relmada Therapeutics's operating income has increased by 21% YoY
Growth
What is Relmada Therapeutics's growth rate over time
Valuation
What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
0.23
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 23% YoY
The P/B is 93% less than the 5-year quarterly average of 3.3 and 86% less than the last 4 quarters average of 1.7
RLMD's equity has plunged by 53% YoY and by 23% from the previous quarter
Efficiency
How efficient is Relmada Therapeutics business performance
Relmada Therapeutics's return on equity has decreased by 39% YoY and by 20% QoQ
The ROA has declined by 31% year-on-year and by 17% since the previous quarter
RLMD's return on invested capital is down by 27% year-on-year and by 18% since the previous quarter
Dividends
What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLMD.
Financial health
How did Relmada Therapeutics financials performed over time
Relmada Therapeutics's total assets has decreased by 49% YoY and by 22% QoQ
The quick ratio has contracted by 47% YoY and by 9% from the previous quarter
RLMD's debt is 100% smaller than its equity
RLMD's equity has plunged by 53% YoY and by 23% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.